Layered defense: how mucus and tight junctions seal the intestinal barrier

Christopher T. Capaldo¹ · Domonica N. Powell² · Daniel Kalman²

Abstract The colonic mucosa provides a vital defensive barrier separating the body from the microbial populations residing in the intestinal lumen. Indeed, growing evidence shows that loss of this barrier may cause disease or exacerbate disease progression. The loss of barrier integrity increases the translocation of bacterial antigens and stimulates inflammation in the intestinal mucosa, which is the central pathological feature of inflammatory bowel diseases (IBDs). This review focuses on how intestinal mucus and intercellular tight junctions (TJs) act together to maintain the integrity of the colonic barrier and how barrier integrity is dysregulated in IBD.

Keywords Mucus · Tight junction · Epithelial barrier · Inflammation · IBD

Introduction

Inflammatory bowel diseases (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), are characterized by chronic or intermittent inflammation of the intestinal mucosa [1]. IBD is an idiopathic and multifactorial condition, and recent studies indicate that both genetic and environmental factors contribute to the disease [2, 3]. During the etiology of IBD, aberrant immune responses triggered by the microbiota itself or excessive leakage of bacterial antigens into the mucosa cause inflammatory responses that progressively degrade the intestinal epithelia. This in turn permits more antigen leak and exacerbates inflammation, further compromising barrier integrity. The mucosal barrier integrity, therefore, is a key determinant of disease initiation, progression, and severity in IBD patients. Disrupting the inflammatory feedback cycle is a fundamental goal of IBD therapy. In experimental models, exposure of epithelial cells to proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) causes cell death, alters the production of secreted mucins, and disrupts the epithelial barriers) [4–8]. Notably, the anti-TNF-α monoclonal antibody, infliximab, a treatment for advanced IBD, short-circuits this inflammatory feedback loop by limiting immune activation and mitigating cytotoxic effects [5].

Epithelial tissue acts not only to separate essential internal organ systems from the outside world but also facilitates communication with the microbiota and absorbs nutrients. Additional features of the colonic barrier include secreted mucus and water absorption. The epithelial layer is composed of a simple monolayer of around 20 billion contiguous cells [9], which, like the skin, continually regenerates. Stem cells, located at the base of the crypts of Lieberkühn, produce daughter cells that differentiate. As the progeny cells migrate toward the luminal surface, they lose their proliferative capacity and differentiate into specialized cells, which include colonocytes and mucin producing goblet cells (Fig. 1) [10, 11]. Cells at the luminal surface eventually undergo programmed cell death (apoptosis) and are shed (Fig. 1). From birth to death, the regenerative process is complete within a few days [12].

Mature cells facing the lumen, termed surface cells, are in close apposition to layers of mucus. The cells and the
mucus together form a layered barrier separating the body from the colonic microflora and limiting influx of bacteria and bacterial antigens. The combination of the epithelial sheet and the mucus layers forms a biologically flexible and environmentally responsive barrier to luminal contents. Indeed, growing evidence shows that loss of barrier integrity may cause disease or exacerbate disease progression (reviewed in [13, 14]). This review focuses on how the mucus and TJs together provide a layered defensive barrier in the colon and how their dysregulation contributes to IBD.

**Mucins separate the epithelia from the intestinal lumen**

The colonic mucosa secretes copious amounts of mucus, which is composed of complex and extensive O-linked oligosaccharide modifications on a mucin protein backbone. These glycoproteins form large disulfide-linked macromolecules, and upon release from goblet cell granules into the lumen, become hydrated and expand to form a net-like gel [15]. Whereas the small intestine contains a single layer of loose unattached mucus, mucus in the colon is organized into three distinct layers. Membrane-anchored mucins associated with the colonic epithelial cells form the glycocalyx. The glycocalyx gives way to a second tightly crosslinked inner layer primarily composed of the mucin protein MUC2. The outermost layer, generated by proteolysis of the inner layer, is less dense and less viscous. A more detailed description of mucin organization in the colon is reviewed elsewhere [16–18].

These mucus layers serve to separate bacteria in the lumen from the epithelia in several ways. First, the mucus layers achieve different densities, such that commensal flora or even pathogens can reside within the low density outer layer [16, 18] but are generally excluded from the high density inner layer and glycocalyx [19]. The outer mucus layers contain diverse carbohydrate motifs, immunoglobulins, and other proteins that serve as binding sites for bacteria [20, 21]. A second means of separating the bacteria is mucus turnover. As secreted mucus is extruded, proteolyzed in the inner layer, and ultimately secreted into the lumen, bound bacteria are expelled and removed from the body by intestinal peristalsis. The mucus layers turn over in a matter of hours, providing dynamic removal of bacteria and limiting their access to the epithelium [22]. Finally, the mucus serves as a lubricant to prevent feces from abrading and tearing the epithelia [22]. Thus, the mucus serves to limit access of bacteria to the epithelia. It is important to note that the density of the mucus does not preclude access of secreted bacterial metabolites or toxins to the epithelia based on size alone. Given the importance of these molecules in epithelial barrier integrity, a role for the mucus in regulating their access promises to be an increasingly important area of investigation.

Defective mucin production or processing has been linked to human IBD. UC patients have fewer goblet cells and decreased synthesis and secretion of MUC2, especially during episodes of severe disease. This allows direct contact of the colonic microbiota with the epithelial barrier [23]. In addition, lower levels of the goblet cell differentiation factors HATH1 and KLF4 were evident in biopsies from patients with active UC [24]. Furthermore, genome-wide association studies (GWAS) have implicated mutations in the MUC genes in IBD pathogenesis, including the membrane-anchored MUC3...
and MUC19 [2, 25]. Moreover, variants of MUC2, the major secreted mucin in the human colon, have been found in IBD cases [26].

Unlike UC patients, CD patients exhibit increased mucus production [24, 27]. However, despite the increased levels, the mucus barrier still fails to restrict bacterial access to the epithelia [28]. These observations suggest that secondary structural modifications, in addition to mucin levels, are critical for function of the mucus barrier. In this regard, it has been proposed that increased bacterial access is due to impaired mucin processing in CD patients, which may affect the length of glycans attached by O-glycosylation [8, 23]. Notably, proper glycosylation, sulfation, and sialylation are essential for the viscoelastic functions of mucus. Humans and mice with IBD have been found to have higher levels of sulfide, a product of sulfate reducing bacteria, that could reduce the disulfide bond between mucins and degrade the mucus network, thus allowing increased microbial contact with the host [29, 30]. Accordingly, glycosylation and sulfation defects have also been found in a UC cohorts, indicating that mucus modification may play a role in limiting barrier function in disease [31–33]. More specifically, mutations in core 1 β3GalT-specific molecular chaperone (Cosmc), a chaperone for the T-synthase glycosyltransferase responsible for the synthesis of the O-glycans on mucin proteins, have also been associated with IBD in GWAS studies [34]. The location of Cosmc on X chromosome may provide an explanation for the male gender bias of IBD [35].

Experimental disease models in mice further strengthen the role the mucus barrier and mucins can play in the prevention or pathogenesis of IBD. For example, 5 weeks after birth, Muc2 knockout animals (Muc2−/−) develop spontaneous colitis and display increased susceptibility to experimental DSS colitis, presumably due to the direct contact of intestinal microbiota with the epithelia [36]. Animal models also demonstrate that glycoprotein modification is crucial to intestinal homeostasis. Mice lacking core 1-derived O-glycans, recapitulating defects in humans with mutations in Cosmc, show loss of mucus complexity and rapid spontaneous colitis [31]. It is important to note that the outer and inner mucous layers of the colon are almost entirely composed of Muc2, and it is expected that Muc2−/− strains would then depend only on the glycocalyx for fecal lubrication [21]. In summary, the secreted mucus barrier appears to function as a means of preventing or limiting contact of bacteria and bacterial antigens with epithelial cells.

The outer layer of colonic mucus is a habitat for both indigeneous and transient microorganisms, called autochthonous and allochthonous, respectively. Changes in the resident autochthonous bacteria appear to have more impact on the host’s health than do changes in transient luminal allochthonous bacteria found in the fecal matter [37]. An imbalance of the microbiota, a state referred to as dysbiosis, is characteristic of IBD, indicating the importance of maintaining the appropriate bacteria in the intestinal mucus [38]. Mucus provides nutrients to bacteria, including amino acids and sugars, which are especially important for those bacteria capable of degrading the glycans on the mucin backbone [39, 40]. Akkermansia muciniphila is a mucus-degrading bacterium underrepresented in many disease states including IBD, obesity, and type 2 diabetes, and numerous studies have correlated the presence of A. muciniphila with a healthy mucosa [41, 42]. Additionally, providing mice with A. muciniphila during high-fat diet (HFD) feeding, which normally results in decreased barrier integrity, led to a restored barrier, increased goblet cell numbers, and prevention of metabolic endotoxemia [42] [43] [44]. Interestingly, bacteriophages within the mucus layer may also dictate the abundance and diversity of bacteria found in the intestine [38]. One study of an IBD cohort demonstrated an inverse correlation between bacteriophage expansion and diversification on the one hand and bacterial diversity on the other, raising the possibility that bacteriophages may contribute to the dysbiotic state in IBD [45]. Taken together, these studies demonstrate the importance of intestinal mucus in supporting growth of protective commensal bacteria as well as facilitating repopulation and maintaining commensal homeostasis to prevent dysbiosis. Accordingly, disruption of the mucus barrier may result in dysbiosis.

**TJs form a paracellular seal**

Epithelial cells are networked together through proteinaceous adhesive contacts called junctions, which both join cells together and provide a paracellular seal. The seal between cells requires tight junctions (TJs), a specialized multipurpose adhesion that simultaneously occludes the paracellular space, dictates ion flux across the tissue, and maintains cellular polarity. The TJs are positioned at the boundary of the apical and lateral membrane surfaces of adjacent epithelial cells in the colon and consist of 5–7 membrane fusion sites called “kissing points” [46, 47]. The entire circumference of each cell is joined to opposing cells via an adhesive TJ band, called a strand. TJ strands in the colon are not linear but rather highly branched structures that form anastomosed webs that extend several hundred nanometers laterally from the apex of the cell. All epithelial cells that line the intestine are joined in this manner.

TJs regulate the flux of ions and solutes on the one hand, termed the “gate function,” and maintain cell polarity on the other, termed the “fence function” [48, 49]. Thus, TJs serve as a barrier to bacteria and bacterial products while also corralling apical plasma membrane proteins, and presumably the glycocalyx mucins, at the lumen-facing domain of the epithelial cell.
The claudin family proteins are essential components of TJs. Claudins form TJ strands by polymerizing within the plasma membrane and dimerizing with claudins on apposing cells, across the extracellular space, to generate the paracellular seal. There are 24 claudin genes in humans, with multiple claudins expressed within any given cell [50]. Importantly, several claudin proteins dimerize to form charge and size-selective ion pores that are vital for ionic homeostasis in epithelial tissues. For example, mice deficient in both claudin 2 and 15 mice fail to equilibrate sodium levels in the luminal space of the small bowel, which leads to low nutrient absorption, wasting disease, and premature death [51]. Other claudins, such as claudin 4, appear to promote a tighter seal; claudin 4 does not form ion pores within the TJ but appears to exclude pore-forming claudin 2 [52]. The permeability of the TJ is thought to derive at least in part from the relative amounts of amounts of pore forming or sealing claudins within the strands, as well as the architecture of the strands, particularly the complexity and numbers of TJ strands [49, 53].

Different complements of claudins are expressed at different levels in epithelia along the length of the intestinal tract, as well as within the intestinal crypts themselves [52] (Fig. 1). For example, our recent studies in mice indicate that 11 claudins are expressed as a gradient within the crypts (Fig. 1) [54]. In general, “leaky” pore forming claudins are restricted to the colonic crypt base, whereas “tight” sealing claudins are more prominently expressed in surface cells facing the lumen.

At the molecular level, the TJ is a highly diverse structure composed of both transmembrane and cytoplasmic proteins [55, 56]. Besides claudins, there exist three additional classes of transmembrane proteins in the TJ: occludin, tricellulin, and junctional adhesion molecules (JAMs) [53, 57–59]. A dense “plaque” of scaffolding molecules is anchored to the transmembrane proteins, which include the Zonula Occludins (ZO) and MAGUK family proteins (reviewed in [49]). These scaffolding proteins link the transmembrane proteins to kinases and signaling molecules that localize at the junction. These molecules in turn control not only cell-cell contacts but also the actin polymerization machinery and contractility apparatus of apically situated actin and myosin [49, 60]. Scaffold proteins have different affinities for claudins and may regulate the types of claudins in the TJs [61]. Likewise, the contractile machinery appears to regulate localization of claudins within the TJs [62–65]. In summary, this molecular signaling apparatus controls claudin localization and function, and thus the permeability of the epithelial barrier.

In addition to forming ion pores, claudin strands have a poorly understood mechanism that permits small molecules to traverse the TJ, termed the paracellular “leak pathway” [66–68]. There is accumulating evidence that TJ strands themselves are dynamic and frequently break, reform, and exchange claudin proteins in response to physiological, environmental, and pathogenic stimuli [52, 63]. However, it remains to be established whether the paracellular leakage results from separation of transcellular dimers, strand breakage, or some other unknown mechanism. Interestingly, several pathogens, including both bacteria and viruses, have evolved means to traverse the paracellular junctions by disrupting claudins, or the actin structures that provide structural integrity to the cell and the TJs (reviewed in [69]). For example, the bacterium Clostridium perfringens secretes a toxin that binds claudins 3 and 4, whereas Hepatitis C virus interacts with claudin 1 [69]. In summary, the composition and numbers of the TJ strands, the type of claudins that compose them, their localization within the intestinal tract, and the intracellular signaling apparatus all contribute to the permeability of the intestinal barrier.

Several lines of evidence implicate dysregulation of the mucosal barrier, and of TJ architecture and claudin expression in particular, in the etiology of IBD [47, 70]. GWAS studies have identified several genes that link TJ function to IBD [2, 71]. Of the IBD implicated genes, one of the best understood is hepatocyte nuclear factor alpha (HNF4a) [72]. HNF4a is a transcription factor involved in the maturation of colonocytes as they migrate out of the crypts. HNF4a regulates claudin expression, including claudin 7 [73]. Moreover, multiple studies have demonstrated a change in TJ transmembrane proteins in IBD patients. Tricellulin, a specialized occludin-like molecule responsible for sealing the TJ at tricellular contacts, is decreased in UC [74, 75]. Moreover, expression of the sealing claudins 1 and 4 is suppressed in IBD patients [70, 76]. Furthermore, upregulation of claudin 2 expression and downregulation of claudin 5 and 8 correlate with barrier dysfunction and active CD [77]. A more comprehensive review of the TJ and TJ-associated proteins dysregulated in IBD can be found elsewhere [75, 78, 79].

Disease phenotypes of human IBD are recapitulated in mice with genetic deficiencies similar to those found in human patients and confirm the importance of altering TJs and barrier integrity in IBD pathogenesis. For example, mice deficient in claudin 7 in the colon develop lethal colitis soon after birth [80, 81]. Notably, based on freeze fracture EM analysis, TJs of wild type and claudin 7 knockout animals have nearly identical structure, yet the character and function of the TJ appears compromised. Without claudin 7, the epithelial barrier is more permeant to small molecules (~400 Da), although the flux of larger molecules (~4 kDa) and the overall balance of Na⁺ and Cl⁻ were unchanged [80]. Therefore, claudin 7 appears to function to selectively regulate permeability of small molecules, and its dysregulation is sufficient to cause disease. The observation that loss of claudin 7 disrupts the TJ seal raised the possibility that this claudin might also limit flux of bacterial antigens. Accordingly, antibiotics ameliorated colitis in mice with claudin 7 deficiency, whereas addition of bacterial antigen (fMLF) reversed this protective effect [80]. Together,
these data support a model of IBD pathogenesis in which dysregulation of TJs facilitates leakage of luminal antigens across the epithelial barrier that trigger inflammation and initiate colitis. Master regulators of claudin expression have also been implicated in mouse models of IBD. As in humans, Hnf4a regulates expression of claudin genes in mice [82, 83]. Accordingly, loss of function alleles of Hnf4a in mice results in dysregulation of claudin expression and spontaneous colitis [84].

**The mucosal barrier, inflammation, and IBD**

The mucosal barrier is not a static structure, and epithelial tight junctions and mucus production both respond to inflammatory stimuli. For example, upon infection, the inflammatory cytokine TNF-α increases epithelial permeability through alterations in TJ function, structure, and dynamics [52, 85]. Yet, TNF-α also increases mucus production by goblet cells to limit the inflammatory response by stemming influx of bacteria through the mucus layers.

Importantly, sustained inflammation or protracted dysregulation of barrier integrity initiates or exacerbates IBD. In this regard, loss or dysregulation of either the mucus or the TJs suffice to cause colitis, an effect that depends upon bacterial or antigen translocation. Thus, mice lacking claudin 7, Hnf4a, and Muc2 all develop spontaneous colitis [72, 80, 86]. The observation that symptoms are relieved under germ-free conditions or after treatment with antibiotics highlights the non-redundant role of the mucus as well as TJs in limiting access of microbes and microbial products to the body and the contribution of bacterial antigens to colitis. Additionally, the mucus barrier and TJs are interdependent such that loss of one diminishes the other. In this regard, Muc2−/− mice display increased epithelia barrier permeability and dysregulated claudin gene expression in addition to defects in the mucus [86]. Likewise, numbers of mucin-producing goblet cells and mucus are diminished in Hnf4a−/− mice [84]. Such interdependence could result from dysregulation of signals that coordinate both the mucus and TJs. Alternatively, inflammation associated with either knock-out phenotype could damage the remaining barrier. In any case, such interdependence may facilitate feedback inflammatory responses that perpetuate IBD.

**Summary and future directions**

The epithelial TJs and the three mucus layers cooperate to form a highly integrated barrier system that together limit access of luminal contents to the body proper. The molecular constituents of this barrier are still being identified and their functions elucidated. Nevertheless, through in vivo and in vitro studies in experimental models, as well as studies of human IBD, an integrated understanding of mucosal barrier function is beginning to emerge. The capacity of the mucus to prevent abrasion and trap bacteria represents the first line of defense, while the paracellular TJ barrier prevents leakage of bacterial antigens from the lumen into the body. Furthermore, the rapid turnover of both mucus and lumen-facing epithelial cells ensures that bacteria that do interact with these structures are constantly being evicted. This multilayer system thus functions to limit bacterial contact with the host while still permitting access of small molecules, including microbial metabolites.

A comprehensive understanding of the epithelial barrier system and its relationship to commensal microbes and to the immune system may provide a more integrated approach to treatment of IBDs. For example, strategies aimed at strengthening both the mucus and epithelia barriers and thereby reducing exposure to inflammatory antigens, coupled with therapeutics that reduce susceptibility of the mucosa to damage caused by bacteria or by inflammatory responses, may restore the intestinal tract of IBD patients to a more benevolent state.

**Acknowledgements** Support for this work was provided by the Broad Medical Research Program Award at the Crohn’s and Colitis Foundation of America (to CTC), as well as a by NIH (2R01DK074731-04A1 to DK).

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. de Souza HS, Fiocchi C (2016) Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 13:13–27
2. McCole DF (2014) IBD candidate genes and intestinal barrier regulation. Inflamm Bowel Dis 20:1829–1849
3. Basoon A, Trotter A, Rodriguez-Palacios A, Cominelli F (2016) Mucosal interactions between genetics, diet, and microbiome in inflammatory bowel disease. Front Immunol 7:290
4. Capaldo CT, Nusrat A (2009) Cytokine regulation of tight junctions. Biochim Biophys Acta 1788:864–871
5. Enss ML, Cornberg M, Wagner S, Gebert A, Henrichs M, Eisenblatter R, Beil W, Kownatzki R, Hedrich HJ (2000) Proinflammatory cytokines trigger MUC gene expression and...
mucin release in the intestinal cancer cell line LS180. Inflamm Res 49:162–169
8. Smirnova MG, Birchall JP, Pearson JP (2000) TNF-alpha in the regulation of MUC5AC secretion: some aspects of cytokine-induced mucin hypersecretion on the in vitro model. Cytokine 12: 1732–1736
9. Nguyen H, Loustauaun F, Facista A, Ramsey L, Hassounah N, Taylor H, Krouse R, Payne CM, Tsikitis VL, Goldschmid S et al (2010) Deficient Pms2, ERCC1, Ku86. CeOM in field defects during progression to colon cancer J Vis Exp DOI: 10.3791/1931
10. Noah TK, Shroyer NF (2013) Notch in the intestine: regulation of homeostasis and pathogenesis. Annu Rev Physiol 75:263–288
11. Biswas S, Davis H, Ishaad S, Sandberg T, Worthley D, Leedham S (2015) Microenvironmental control of stem cell fate in intestinal homeostasis and disease. J Pathol 237:135–145
12. Barker N (2014) Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. Nat Rev Mol Cell Biol 15:19–33
13. Nalle SC, Turner JR (2015) Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease. Mucosal Immunol 8:720–730
14. Weber CR, Turner JR (2007) Inflammatory bowel disease: is it really just another break in the wall? Gut 56:6–8
15. Johansson ME, Sjovall H, Hansson GC (2013) The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 10:352–361
16. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA (2008) Mucins in the mucosal barrier to infection. Mucosal Immunol 1:183–197
17. Perez-Vilar J, Hill RL (1999) The structure and assembly of secreted mucins. J Biol Chem 274:31751–31754
18. McGuckin MA, Linden SK, Sutton P, Florin TH (2011) Mucin dynamics and enteric pathogens. Nat Rev Microbiol 9:265–278
19. Johansson ME, Sjovall H, Hansson GC (2013) The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 10:352–361
20. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA (2008) Mucins in the mucosal barrier to infection. Mucosal Immunol 1:183–197
21. Perez-Vilar J, Hill RL (1999) The structure and assembly of secreted mucins. J Biol Chem 274:31751–31754
22. Johansson ME, Sjovall H, Hansson GC (2013) The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 10:352–361
23. Sun J, Shen X, Li Y, Guo Z, Zhu W, Zuo L, Zhao J, Gu L, Gong J (2016) Therapeutic potential to modify the mucus barrier in inflammatory bowel disease? Trends Mol Med 22:190–199
24. Derrien M, van Passel MW, van de Bovenkamp JH, Schipper RG, van der Meer R, Dekker J, Van Seuningen I, Renes IB et al (2006) Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131:117–129
25. Kudelka MR, Hinrichs BH, Darby T, Moreno CS, Nishio H, Cutler CE, Wang J, Wu H, Zeng J, Wang Y et al (2016) Cosmc is an X-linked inflammatory bowel disease risk gene that spatially regulates mucin glycoproteins. PLoS One 7:e41009
26. Visschedijk MC, Alberts R, Mucha S, Deelen P, de Jong DJ, Seuningen I, Renes IB et al (2006) Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131:117–129
27. Tailford LE, Crost EH, Kavanagh D, Juge N (2015) Mucin glycans foraging in the human gut microbiome. Front Genet 6:81
28. Derrien M, van Passel MW, van de Bovenkamp JH, Schipper RG, de Vos WM, Dekker J (2010) Mucin-bacterial interactions in the human oral cavity and digestive tract. Gut Microbes 1:183–197
29. Rajilic-Stojanovic M, Shanahan F, Guarner F, de Vos WM (2013) Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis 19:481–488
30. Everard A, Belzer C, Geurts L, Ouwwerkerk JP, Draart C, Bindels LB, Guiot Y, Derrien M, Mucicoli GG, Delzenne NM et al (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110:9066–9071
31. Allen A, Rhodes J (1994) Thickness of adherent mucus gel on colon mucosa in humans and its relevance to colitis. Gut 35: 353–359
32. Johansson ME, Gustafsson JK, Holmen-Larsson J, Jabbas KS, Xia L, Xu H, Ghishak FK, Carvalho FA, Gewirtz AT, Sjovall H et al (2014) Bacteria penetrate the normally impermeable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 63:281–291
33. Tailford LE, Crost EH, Kavanagh D, Juge N (2015) Mucin glycans foraging in the human gut microbiome. Front Genet 6:81
34. Derrien M, van Passel MW, van de Bovenkamp JH, Schipper RG, de Vos WM, Dekker J (2010) Mucin-bacterial interactions in the human oral cavity and digestive tract. Gut Microbes 1:183–197
35. Kudelka MR, Hinrichs BH, Darby T, Moreno CS, Nishio H, Cutler CE, Wang J, Wu H, Zeng J, Wang Y et al (2016) Cosmc is an X-linked inflammatory bowel disease risk gene that spatially regulates mucin glycoproteins. PLoS One 7:e41009
36. Visschedijk MC, Alberts R, Mucha S, Deelen P, de Jong DJ, Seuningen I, Renes IB et al (2006) Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131:117–129
37. Tailford LE, Crost EH, Kavanagh D, Juge N (2015) Mucin glycans foraging in the human gut microbiome. Front Genet 6:81
38. Derrien M, van Passel MW, van de Bovenkamp JH, Schipper RG, de Vos WM, Dekker J (2010) Mucin-bacterial interactions in the human oral cavity and digestive tract. Gut Microbes 1:183–197
39. Rajilic-Stojanovic M, Shanahan F, Guarner F, de Vos WM (2013) Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis 19:481–488
40. Everard A, Belzer C, Geurts L, Ouwwerkerk JP, Draart C, Bindels LB, Guiot Y, Derrien M, Mucicoli GG, Delzenne NM et al (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110:9066–9071
44. Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW (2014) An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63:727–735

45. Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Kambal A, Monaco CL, Zhao G, Flesher P et al (2015) Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160:447–460

46. Farquhar MG, Palade GE (1963) Junctional complexes in various epithelia. J Cell Biol 17:375–412

47. Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss HD, Bentzel CJ, Riecken EO, Schulze JD (1999) Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 116:301–309

48. Diamond JM (1977) Twenty-first Bowditch Lecture. The epithelial junction: bridge, gate, and fence. Physiologist 20:10–18

49. Zihni C, Mills C, Matter K, Balda MS (2016) Claudin switching: physiological plasticity of the tight junction. Semin Cell Dev Biol 42:22–29

50. Mineta K, Yamamoto Y, Yamazaki Y, Tanaka H, Tada Y, Saito K, Takamura A, Ishigaki A, Endo T, Takeuchi K et al (2011) Predicted expansion of the claudin multigene family. FEBS Lett 585:606–612

51. Wada M, Tamura A, Takahashi N, Tsukita S (2013) Loss of claudins 2 and 15 from mice causes defects in paracellular Na+ flow and nutrient transport in gut and leads to death from malnutrition. Gastroenterology 144:369–380

52. Capaldo CT, Nusrat A (2015) Claudin switching: physiological plasticity of the tight junction. Semin Cell Dev Biol 42:22–29

53. Tsukita S, Furuse M, Itoh M (2001) Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2:285–293

54. Lili LN, Yamsaengvisel T, Jiang L, Filbin MT (2015) Claudin-1–17: a diverse family of transmembrane proteins. Front Mol Neurosci 8:171

55. Tang VW (2006) Proteomic and bioinformatic analysis of epithelial apical junctions. Front Biosci 13:6662–6680

56. Fanning AS, Van Itallie CM, Anderson JM (2012) Zonula occludens-1 is a key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 139:550–564

57. Farquhar MG, Palade GE (1963) Junctional complexes in various epithelia. J Cell Biol 17:375–412

58. Ikenouchi J, Furuse M, Furuse K, Sasaki H, Tsukita S, Tsukita S (1993) Occludin: a novel integral membrane protein located at cell-cell junctions. Cell 74:925–934

59. Martin-Padura I, Lossiagio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A et al (1998) Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 142:117–127

60. Fanning AS, Van Itallie CM, Anderson JM (2012) Zonula occludens-1 and -2 regulate apical cell structure and the zonula adherens cytoskeleton in polarized epithelia. Mol Biol Cell 23:577–590

61. Itoh M, Furuse M, Morita K, Kubota K, Saitou M, Tsukita S (1999) Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 123:1777–1788

62. Ikenouchi J, Furuse M, Furuse K, Sasaki H, Tsukita S, Tsukita S (2005) Occludin: a novel barrier at tricellular tight junctions. J Cell Biol 171:939–945

63. Martin-Padura I, Lossiagio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A et al (1998) Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 142:117–127

64. Fanning AS, Van Itallie CM, Anderson JM (2012) Zonula occludens-1 and -2 regulate apical cell structure and the zonula adherens cytoskeleton in polarized epithelia. Mol Biol Cell 23:577–590

65. Itoh M, Furuse M, Morita K, Kubota K, Saitou M, Tsukita S (1999) Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 123:1777–1788

66. Ivanov AI (2008) Actin motors that drive formation and disassembly of epithelial apical junctions. Front Biosci 13:6662–6681

67. Van Itallie CM, Tietgens AJ, Anderson JM (2016) Visualizing the dynamic coupling of claudin strands to the actin cytoskeleton through ZO-1. Mol Biol Cell DOI. doi:10.1091/mbc.E16-10-0698

68. Cunningham KE, Turner JR (2012) Myosin light chain kinase: pulling the strings of epithelial tight junction function. Ann N Y Acad Sci 1258:34–42

69. Quiros M, Nusrat A (2014) Rhodopsin signaling and regulation of the epithelial apical junctional complex. Semin Cell Dev Biol 36:194–203

70. Weber CR (2012) Dynamic properties of the tight junction barrier. Ann N Y Acad Sci 1257:77–84

71. Shen L, Weber CR, Raleigh DR, Yu D, Turner JR (2011) Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol 73:283–309

72. Van Itallie CM, Holmes J, Bridges A, Gookin JL, Coccoro MR, Proctor W, Colegio OR, Anderson JM (2008) The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J Cell Biol 121:298–305

73. Guttmann JA, Finlay BB (2009) Tight junctions as targets of infectious agents. Biochem Biophys Acta 1788:832–841

74. Hering NA, Fromm M, Schulze JD (2012) Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol 590:1035–1044

75. Meddings J (2008) What role does intestinal permeability have in IBD pathogenesis? Inflamm Bowel Dis 14(Suppl 2):S138–S139

76. Ahn SH, Shah YM, Inoue J, Morimura K, Kim I, Yim S, Lambert G, Kurdtani R, Nagashima K, Gonzalez FJ et al (2008) Hepatocyte nuclear factor-4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis 14:908–920

77. Farkas AE, Hilgarth RS, Capaldo CT, Gerner-Smith C, Powell DR, Vertino PM, Koval M, Parkos CA, Nusrat A (2015) HNF-4alpha regulates claudin-7 protein expression during intestinal epithelial differentiation. Am J Physiol 185:2206–2218

78. Krug SM, Amasheh S, Richter JF, Milatz S, Gunzel D, Westphal JK, Huber O, Schulze JD, Fromm M (2009) Tricellulin forms a barrier to macromolecules in tricellular tight junctions without affecting ion permeability. Mol Cell Biol 20:3713–3724

79. Schulze JD, Gunzel D, John LJ, Fromm M (2012) Perspectives on tight junction research. Ann N Y Acad Sci 1257:1–19

80. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, Burcher N, Fromm M et al (2005) Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129:550–564

81. Zeissig S, Burdell N, Gunzel D, Richter J, Mankertz J, Wahnschaffe U, Kroesen AJ, Zetze M, Fromm M, Schulze JD (2007) Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut 56:61–72

82. Ahmad R, Sorrell MF, Batra SK, Dhawan P, Singh AB (2017) Gut permeability and mucosal inflammation: bad, good or context dependent. Mucosal Immunol 10:307–317

83. Garcia-Hernandez V, Quiros M, Nusrat A (2017) Intestinal epithelial claudins: expression and regulation in homeostasis and inflammation. Ann N Y Acad Sci DOI. doi:10.1111/nyas.13360

84. Tanaka H, Takechi M, Kiyonari H, Shioi G, Tamura A, Tsukita S (2015) Intestinal deletion of Claudin-7 enhances paracellular organic solute flux and initiates colonic inflammation in mice. Gut 64:1529–1538

85. Ding L, Lu Z, Foreman O, Tatum R, Lu Q, Renegar R, Cao J, Chen YH (2012) Inflammation and disruption of the mucosal architecture in claudin-7-deficient mice. Gastroenterology 142:305–315

86. van Sommeren S, Visschedijk MC, Festen EA, de Jong DJ, Ponsioen CY, Wijmenga C, Weersma RK (2011) HNF-4alpha and CDE1 are associated with ulcerative colitis in a Dutch cohort. Inflamm Bowel Dis 17:1714–1718

87. Cattin AL, Le Beyec J, Barreau F, Saint-Just S, Houllier A, Gonzalez FJ, Robine S, Pincon-Raymond M, Cardot P, Lacasa M et al (2009) Hepatocyte nuclear factor 4alpha, a key factor for...
homeostasis, cell architecture, and barrier function of the adult intestinal epithelium. Mol Cell Biol 29:6294–6308

84. Darsigny M, Babeu JP, Dupuis AA, Furth EE, Seidman EG, Levy E, Verdu EF, Gendron FP, Boudreau F (2009) Loss of hepatocyte-nuclear-factor-4alpha affects colonic ion transport and causes chronic inflammation resembling inflammatory bowel disease in mice. PLoS One 4:e7609

85. Cornick S, Tawiah A, Chadee K (2015) Roles and regulation of the mucus barrier in the gut. Tissue Barriers 3:e982426

86. Lu P, Burger-van Paassen N, van der Sluis M, Witte-Bouma J, Kerckaert JP, van Gouwdeever JB, Van Seuningen I, Renes IB (2011) Colonic gene expression patterns of mucin Muc2 knockout mice reveal various phases in colitis development. Inflamm Bowel Dis 17:2047–2057